DEF 14A: Sangamo Therapeutics Seeks Stockholder Approval for Amended Equity Incentive Plan and Director Elections

Sangamo Therapeutics is holding its annual stockholder meeting to vote on director elections, executive compensation, and an amendment to its equity incentive plan.

Summary

• Sangamo Therapeutics is soliciting proxies for its 2025 Annual Meeting of Stockholders to be held on June 12, 2025, virtually.
• The proposals include the election of nine directors, an advisory vote on executive compensation, approval of an amendment and restatement of the 2018 Equity Incentive Plan to increase the share reserve by 14,000,000 shares, and ratification of Ernst & Young LLP as the independent auditor for the year ending December 31, 2025.
• The Board recommends voting FOR all proposals.
• The record date for the Annual Meeting is April 17, 2025.
• The company is seeking approval to increase the aggregate number of shares of common stock that may be issued under the Amended 2018 Plan by 14,000,000 shares.
• The company is also seeking approval to increase the aggregate maximum number of shares of common stock that may be issued pursuant to the exercise of incentive stock options under the Amended 2018 Plan by 28,000,000 shares (for a total of 123,200,000 shares).

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, so the sentiment is neutral to positive. The company is seeking approval for routine matters and highlighting its commitment to stockholders.

Positives

• The Board of Directors is actively engaged with stockholders and responsive to their views.
• The company has a Code of Conduct and Insider Trading Policy in place.
• The company has a clawback policy in place.
• The company prohibits hedging, pledging, and speculative transactions related to its securities by directors, officers, and employees.

Negatives

• The company is seeking to increase the number of shares available under its equity incentive plan, which could dilute existing stockholders.
• The company's burn rate for 2024 was 6.04%.

Risks

• The company's success depends on its ability to attract and retain qualified executives.
• Biotechnology research, development, and commercialization involve a high degree of risk.
• The acceleration of vesting of an award in the event of a change in control or hostile takeover under the Amended 2018 Plan may be viewed as an anti-takeover provision, which may have the effect of discouraging a proposal to acquire or otherwise obtain control of us.

Future Outlook

The company expects the share authorization under the Amended 2018 Plan to provide enough shares for awards for approximately one to two years.

Management Comments

• A priority for our Board of Directors is soliciting and listening to the views of our stockholders on a variety of topics, including our business and growth strategy, corporate governance practices and executive compensation matters.
• Our discussions with our investors have been productive and informative and have provided valuable feedback to our Board of Directors to help ensure that our Boards decisions are aligned with stockholder objectives.

Industry Context

The company operates in the highly competitive biotechnology and pharmaceutical industry, particularly in the San Francisco Bay Area.

Comparison to Industry Standards

• The Compensation Committee reviewed market data for each named executive officers position, compiled by Aon, from a peer group of companies.
• The company's peer group includes Adverum Biotechnologies, bluebird bio, Agenus, Editas Medicine, Alector, FibroGen, Allogene Therapeutics, Fulcrum Therapeutics, ALX Oncology, Gritstone bio, AnaptysBio, Mersana Therapeutics, Arcturus Therapeutics, Nektar Therapeutics, Atara Biotherapeutics, NGM Biopharmaceuticals, Atea Pharmaceuticals, REGENIXBIO, Aura Biosciences, and Scholar Rock.

Stakeholder Impact

• Approval of the equity incentive plan amendment will impact employees, directors, and stockholders.
• The election of directors will determine the leadership and oversight of the company.

Next Steps

• Stockholders are encouraged to vote on the proposals.
• The company will file a Registration Statement on Form S-8 with the SEC with respect to the shares of our common stock to be registered pursuant to the Amended 2018 Plan, as soon as reasonably and commercially practicable following stockholder approval.

Key Dates

Keywords

proxy statement, stockholders, equity incentive plan, directors, executive compensation, governance, Sangamo Therapeutics